Radioactive 'Tumor-Seeking' therapy battles advanced prostate cancer in major trial

NCT ID NCT04647526

Ongoing Disease control Sponsor: POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company Source: ClinicalTrials.gov ↗

Summary

This study is testing whether a new radioactive drug that targets prostate cancer cells (called [Lu-177]-PNT2002) works better than standard hormone drugs for men with advanced prostate cancer that has spread and is no longer controlled by standard treatments. About 455 men whose cancer shows a specific marker (PSMA) on a special scan will receive either the new therapy or a standard drug. The main goal is to see which treatment better delays the cancer from getting worse.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Arizona Institute of Urology (AIU) - Tucson

Tucson, Arizona, 85704, United States
Astera Cancer Care

East Brunswick, New Jersey, 08816, United States
BC Cancer - Vancouver

Vancouver, British Columbia, V5Z 4E6, Canada
CHU of Quebec - Laval University

Québec, Quebec, G1R 2J6, Canada
CHUM - University Hospital of Montreal

Montreal, Quebec, H2X 3E4, Canada
Carolina Urologic Research Center

Myrtle Beach, South Carolina, 29572, United States
Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute

Los Angeles, California, 90048, United States
Center Jean Perrin, Department of Medical Oncology

Clermont-Ferrand, 63011, France
Charing Cross Hospital, Department of Medical Oncology

London, United Kingdom
Chesapeake Urology Associates (CUA) P.A.

Towson, Maryland, 21204, United States
Claude Huriez Hospital

Lille, 59037, France
Dallas VA Medical Center, Nuclear Medicine Service

Dallas, Texas, 75216, United States
Erasmus University Medical Center Rotterdam

Rotterdam, 3015 GD, Netherlands
Excel Diagnostics & Nuclear Oncology Center

Houston, Texas, 77402, United States
Fox Chase Cancer Center

Philadelphia, Pennsylvania, 19111, United States
Greater Dayton Cancer Center

Kettering, Ohio, 45409, United States
H. Lee Moffitt Cancer Center & Research Institute

Tampa, Florida, 33612, United States
Hoag Memorial Hospital Presbyterian

Newport Beach, California, 92663, United States
Jewish General Hospital

Montreal, Quebec, H3T 1E2, Canada
Karmanos Cancer Center

Detroit, Michigan, 48201, United States
La Timone Hospital, Nuclear Medicine Department

Marseille, 13385, France
Leon Berard Center

Lyon, 69373, France
London Health Sciences Center - Victoria Hospital

London, Ontario, N6A 5W9, Canada
Montpellier Cancer Institute, Department of Nuclear Medicine

Montpellier, 34298, France
New Mexico Oncology Hematology Consultants Ltd., New Mexico Cancer Center

Albuquerque, New Mexico, 87109, United States
New York Presbyterian Hospital/Weill Cornell Medical Center

New York, New York, 10065, United States
Norrlands University Hospital, Department of Radiation Sciences, Oncology

Umeå, Sweden
Nova Scotia Health Authority

Halifax, Nova Scotia, B3H 2Y9, Canada
Perelman Center for Advanced Medicine

Philadelphia, Pennsylvania, 19104, United States
Princess Margaret Cancer Centre

Toronto, Ontario, M5G 2M9, Canada
Radboud University Medical Center (Radboudumc)

Nijmegen, Netherlands
Royal Marsden NHS Foundation Trust - Institute of Cancer Research

Sutton, United Kingdom
Sahlgrenska University Hospital

Gothenburg, 41345, Sweden
Saint Louis University Hospital

St Louis, Missouri, 63110, United States
St. Antonius Hospital

Nieuwegein, Netherlands
Stanford Cancer Institute

Palo Alto, California, 94305, United States
Sunnybrook Research Institute, Odette Cancer Center

Toronto, Ontario, M4N 3M5, Canada
Swedish Cancer Institute Research

Seattle, Washington, 98104, United States
Tenon Hospital, Department of Medical Oncology

Paris, 75020, France
Tri-State Urologic Services

Cincinnati, Ohio, 45212, United States
Tulane University Medical Center

New Orleans, Louisiana, 70112, United States
UC Irvine Chao Family Comprehensive Cancer Center

Orange, California, 92868, United States
UT Southwestern Medical Center

Dallas, Texas, 75390, United States
University of California Los Angeles, Nuclear Medicine Clinic

Los Angeles, California, 90095, United States
University of Colorado Hospital

Aurora, Colorado, 80045, United States
University of Iowa Hospitals and Clinics

Iowa City, Iowa, 52242, United States
University of Kentucky Chandler Medical Center

Lexington, Kentucky, 40536, United States
University of Maryland Greenebaum Cancer Center

Baltimore, Maryland, 21201, United States
University of Michigan Hospitals

Ann Arbor, Michigan, 48109, United States
Urology Cancer Center, PC

Omaha, Nebraska, 68130, United States
VA Greater Los Angeles Healthcare System

Los Angeles, California, 90073, United States
VA St. Louis Health Care System

St Louis, Missouri, 63106, United States
Vanderbilt-Ingram Cancer Center

Nashville, Tennessee, 37232, United States
Washington University School of Medicine

St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER